456 related articles for article (PubMed ID: 24988203)
21. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia.
Nickel JC; Downey J; Young I; Boag S
BJU Int; 1999 Dec; 84(9):976-81. PubMed ID: 10571623
[TBL] [Abstract][Full Text] [Related]
22. Observational study: daily treatment with a new compound "Tradamixina" plus serenoa repens for two months improved the lower urinary tract symptoms.
Iacono F; Prezioso D; Illiano E; Ruffo A; Romeo G; Amato B
BMC Surg; 2012; 12 Suppl 1(Suppl 1):S22. PubMed ID: 23173650
[TBL] [Abstract][Full Text] [Related]
23. Feasibility of holmium laser enucleation of the prostate (HoLEP) for recurrent/residual benign prostatic hyperplasia (BPH).
Elshal AM; Elmansy HM; Elhilali MM
BJU Int; 2012 Dec; 110(11 Pt C):E845-50. PubMed ID: 22702908
[TBL] [Abstract][Full Text] [Related]
24. [Surgery (TUR-P) as a recommended initial treatment modality for the presented case].
Gotoh M
Hinyokika Kiyo; 2005 Sep; 51(9):603-8. PubMed ID: 16229373
[TBL] [Abstract][Full Text] [Related]
25. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study.
Morgia G; Mucciardi G; Galì A; Madonia M; Marchese F; Di Benedetto A; Romano G; Bonvissuto G; Castelli T; Macchione L; Magno C
Urol Int; 2010; 84(4):400-6. PubMed ID: 20332612
[TBL] [Abstract][Full Text] [Related]
26. Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia.
Hasui Y; Marutsuka K; Asada Y; Ide H; Nishi S; Osada Y
Prostate; 1994 Aug; 25(2):91-6. PubMed ID: 7518599
[TBL] [Abstract][Full Text] [Related]
27. [The results of long-term permixon treatment in patients with symptoms of lower urinary tracts dysfunction due to benign prostatic hyperplasia].
Pytel' IuA; Lopatkin NA; Gorilovskiĭ LM; Vinarov AZ; Sivkov AV; Medvedev AA
Urologiia; 2004; (2):3-7. PubMed ID: 15114742
[TBL] [Abstract][Full Text] [Related]
28. Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection.
Magri V; Trinchieri A; Montanari E; Del Nero A; Mangiarotti B; Zirpoli P; de Eguileor M; Marras E; Ceriani I; Vral A; Perletti G
Arch Ital Urol Androl; 2007 Jun; 79(2):84-92. PubMed ID: 17695414
[TBL] [Abstract][Full Text] [Related]
29. Amelioration of testosterone induced benign prostatic hyperplasia by Prunus species.
Jena AK; Vasisht K; Sharma N; Kaur R; Dhingra MS; Karan M
J Ethnopharmacol; 2016 Aug; 190():33-45. PubMed ID: 27235020
[TBL] [Abstract][Full Text] [Related]
30. Can the effect of antibiotherapy and anti-inflammatory therapy on serum PSA levels discriminate between benign and malign prostatic pathologies?
Erol H; Beder N; Calişkan T; Dündar M; Unsal A; Culhaci N
Urol Int; 2006; 76(1):20-6. PubMed ID: 16401916
[TBL] [Abstract][Full Text] [Related]
31. Asymptomatic inflammation and/or infection in benign prostatic inflammation.
Irani J; Goujon JM
BJU Int; 2000 Jun; 85(9):1155-6. PubMed ID: 10939872
[No Abstract] [Full Text] [Related]
32. Dietary supplements for benign prostatic hyperplasia: an overview of systematic reviews.
Kim TH; Lim HJ; Kim MS; Lee MS
Maturitas; 2012 Nov; 73(3):180-5. PubMed ID: 22883375
[TBL] [Abstract][Full Text] [Related]
33. Phytotherapy for benign prostatic hyperplasia.
Gerber GS
Curr Urol Rep; 2002 Aug; 3(4):285-91. PubMed ID: 12149159
[TBL] [Abstract][Full Text] [Related]
34. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
Tsukamoto T; Masumori N; Rahman M; Crane MM
Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
[TBL] [Abstract][Full Text] [Related]
35. Effect of the ratio of resected tissue in comparison with the prostate transitional zone volume on voiding function improvement after transurethral resection of prostate.
Park HK; Paick SH; Lho YS; Jun KK; Kim HG
Urology; 2012 Jan; 79(1):202-6. PubMed ID: 22014961
[TBL] [Abstract][Full Text] [Related]
36. The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS.
Salah Azab S; Elsheikh MG
Aging Male; 2015 Jun; 18(2):89-92. PubMed ID: 25295872
[TBL] [Abstract][Full Text] [Related]
37. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.
Boyle P; Robertson C; Lowe F; Roehrborn C
BJU Int; 2004 Apr; 93(6):751-6. PubMed ID: 15049985
[TBL] [Abstract][Full Text] [Related]
38. A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency.
Sudeep HV; Thomas JV; Shyamprasad K
BMC Urol; 2020 Jul; 20(1):86. PubMed ID: 32620155
[TBL] [Abstract][Full Text] [Related]
39. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study.
Maria G; Brisinda G; Civello IM; Bentivoglio AR; Sganga G; Albanese A
Urology; 2003 Aug; 62(2):259-64; discussion 264-5. PubMed ID: 12893330
[TBL] [Abstract][Full Text] [Related]
40. [A clinical analysis of benign prostatic hyperplasia with chronic prostatitis].
Wu XJ; Yang LY; Zhang XZ
Zhonghua Nan Ke Xue; 2008 Jun; 14(6):527-9. PubMed ID: 18649752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
